538 Harnessing cross-dressing dendritic cells to strengthen anti-tumor immunity
نویسندگان
چکیده
منابع مشابه
Harnessing Oncolytic Virus-Mediated Anti-Tumor Immunity
Oncolytic viruses (OVs) selectively infect, replicate in, and kill tumor cells. For a long time, the therapeutic efficacy of OVs was thought to depend mainly on this mechanism of direct viral oncolysis. Nowadays, however, the post-oncolytic anti-tumor activity induced by the OV therapy is considered a key factor for an efficient therapeutic activity. The research topic addresses these issues an...
متن کاملHarnessing Dendritic Cells for Tumor Antigen Presentation
Dendritic cells (DC) are professional antigen presenting cells that are crucial for the induction of anti-tumor T cell responses. As a consequence, research has focused on the harnessing of DCs for therapeutic interventions. Although current strategies employing ex vivo-generated and tumor-antigen loaded DCs have been proven feasible, there are still many obstacles to overcome in order to impro...
متن کاملTumor-Altered Dendritic Cell Function: Implications for Anti-Tumor Immunity
Dendritic cells (DC) are key regulators of both innate and adaptive immunity, and the array of immunoregulatory functions exhibited by these cells is dictated by their differentiation, maturation, and activation status. Although a major role for these cells in the induction of immunity to pathogens has long been appreciated, data accumulated over the last several years has demonstrated that DC ...
متن کاملHarnessing Human Cross-Presenting CLEC9A+XCR1+ Dendritic Cells for Immunotherapy
1 Mater Research Institute, University of Queensland, Brisbane, QLD, Australia 2 School of Medicine, University of Queensland, Brisbane, QLD, Australia 3 Centre for Biomedical Research, Burnet Institute, Melbourne, VIC, Australia 4 Department of Immunology, Monash University, Melbourne, VIC, Australia 5 School of Biomedical Sciences, University of Queensland, Brisbane, QLD, Australia *Correspon...
متن کاملTherapeutic Use of Dendritic Cells to Promote the Extranodal Priming of Anti-Tumor Immunity
Ectopic lymphoid tissue, also known as tertiary lymphoid organs (TLO) develop adaptively within sites of chronic tissue inflammation, thereby allowing the host to efficiently crossprime specific immune effector cells within sites of disease. Recent evidence suggests that the presence of TLO in the tumor microenvironment (TME) predicts better overall survival. We will discuss the relevance of ex...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal for ImmunoTherapy of Cancer
سال: 2020
ISSN: 2051-1426
DOI: 10.1136/jitc-2020-sitc2020.0538